US Bancorp’s Endocyte, Inc. Common Stock ECYT Stock Holding History

US Bancorp’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,000	Closed	-$36K	–	3792
2018 Q3	$36K	Hold	2,000	–	–	﹤0.01%	2718
2018 Q2	$28K	Buy	+2,000	New	+$23.7K	﹤0.01%	2825
2016 Q1	–	Sell	-400	Closed	-$2K	–	3732
2015 Q4	$2K	Hold	400	–	–	﹤0.01%	3478
2015 Q3	$2K	Buy	+400	New	+$2.09K	﹤0.01%	3462

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

US Bancorp's ECYT Position: Q4 2018 in Review

US Bancorp sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 2,000 shares — an estimated $36K sold.

US Bancorp first reported a position in ECYT in Q3 2015 and held it in 4 quarters. The position peaked at $36K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

US Bancorp reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
US Bancorp sold 2,000 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $36K.
US Bancorp first reported a position in Endocyte, Inc. Common Stock in Q3 2015 and held it in 4 quarters.
US Bancorp's Endocyte, Inc. Common Stock position peaked at $36K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on US Bancorp's 13F filing for Q4 2018, filed 13 Feb 2019.